Major cable and broadcast news outlets seem to have largely ignored a Wall Street Journal report that Donald Trump Jr. stands to potentially benefit financially from a deal between BlinkRx and the government-run TrumpRx pharmaceutical program. Apparently, neither The New York Times or The Washington Post covered the Journal’s findings either.